Showing results (11-20 of 83) with videos related to
Sort By:
Pageof 9
Archives of Dermatology|July 1, 1989
Cutaneous Rhizopus and Aspergillus infections in five patients with cancerN Khardori, S Hayat, K Rolston, et al.Journal of Pediatric Endocrinology & Metabolism : JPEM|October 1, 1995
Does primary salt wasting occur in 11-beta-hydroxylase deficiency?C Singer-Granick, I D Hill, R K RolstonAntimicrobial Agents and Chemotherapy|April 1, 1993
In vitro antimicrobial susceptibilities of Nocardia speciesN Khardori, R Shawar, R Gupta, et al.Chemotherapy|January 1, 1988
In vitro activity of fleroxacin (Ro23-6240), a new fluorinated 4-quinolone against isolates from cancer patientsK Rolston, D H Ho, B LeBlanc, et al.Antimicrobial Agents and Chemotherapy|March 1, 1994
A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapyS Vartivarian, E Anaissie, G Bodey, et al.Reviews of Infectious Diseases|November 1, 1985
Aztreonam plus vancomycin (plus amikacin) vs. moxalactam plus ticarcillin for the empiric treatment of febrile episodes in neutropenic cancer patientsP Jones, K Rolston, V Fainstein, et al.Reviews of Infectious Diseases|March 1, 1990
Prophylaxis of oropharyngeal candidiasis with fluconazoleG Samonis, K Rolston, C Karl, et al.Antimicrobial Agents and Chemotherapy|August 1, 1990
In vitro susceptibility of Xanthomonas (Pseudomonas) maltophilia to newer antimicrobial agentsN Khardori, A Reuben, B Rosenbaum, et al.European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|August 1, 1996
Imipenem or cefoperazone-sulbactam combined with vancomycin for therapy of presumed or proven infection in neutropenic cancer patientsG Bodey, D Abi-Said, K Rolston, et al.The American Journal of Medicine|July 25, 1988
Cefoperazone plus mezlocillin for empiric therapy of febrile cancer patientsP Jones, G P Bodey, K Rolston, et al.Pageof 9